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Abstract
Numerous efforts have been made to elucidate the etiology and improve the treatment of lung cancer, but the overall five-
year survival rate is still only 15%. Identification of prognostic biomarkers for lung cancer using gene expression microarrays
poses a major challenge in that very few overlapping genes have been reported among different studies. To address this
issue, we have performed concurrent genome-wide analyses of copy number variation and gene expression to identify
genes reproducibly associated with tumorigenesis and survival in non-smoking female lung adenocarcinoma. The genomic
landscape of frequent copy number variable regions (CNVRs) in at least 30% of samples was revealed, and their aberration
patterns were highly similar to several studies reported previously. Further statistical analysis for genes located in the CNVRs
identified 475 genes differentially expressed between tumor and normal tissues (p,10
25). We demonstrated the
reproducibility of these genes in another lung cancer study (p=0.0034, Fisher’s exact test), and showed the concordance
between copy number variations and gene expression changes by elevated Pearson correlation coefficients. Pathway
analysis revealed two major dysregulated functions in lung tumorigenesis: survival regulation via AKT signaling and
cytoskeleton reorganization. Further validation of these enriched pathways using three independent cohorts demonstrated
effective prediction of survival. In conclusion, by integrating gene expression profiles and copy number variations, we
identified genes/pathways that may serve as prognostic biomarkers for lung tumorigenesis.
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Introduction
Lung cancer is the leading cause of cancer death in developed
countries, and non-small cell lung carcinoma (NSCLC) accounts
for the majority of lung cancers. Among NSCLCs, adenocarcino-
ma and squamous cell carcinoma are the two major histological
types, representing 60–70% of all lung cancers. In Taiwan, most
lung cancers are adenocarcinoma as well, especially among non-
smoking female patients, and lung cancer mortality rates have
become the highest in the world [1]. Even though numerous
research efforts have been devoted to the development of lung
cancer treatment over the past few decades, the overall five-year
survival rate is still about 15% [2], mainly due to late diagnosis
and/or lack of effective therapeutic methods. To better elucidate
lung cancer etiology and identify prognostic gene sets, many
studies have performed microarray analysis of gene expression
profiles. While the identified gene sets indeed show significant
associations with survival in their respective datasets, very few
genes are common to all the different studies [3]. The discrepancy
in the results of gene expression analysis may result from multiple
experimental protocols, different statistical approaches, or inho-
mogeneous cohort characteristics. One possible strategy to
increase homogeneity in these findings is to analyze gene
expression in conjunction with DNA-level changes such as copy
number variations (CNVs).
DNA copy number has played an important role in recent
cancer studies. It explains about 12% of gene expression variations
in breast cancer [4], and concordance between changes in mRNA
expression levels and copy number has been observed in several
genes located in copy number variable regions (CNVRs) in lung
cancer [5,6]. Furthermore, gene copy numbers have proven useful
in predicting patient survival in lung cancer [7,8]. For example,
the overexpression and amplification of epidermal growth factor
receptor (EGFR) [9], and the underexpression and loss of dual
specificity phosphate 4 (DUSP4), correlate strongly with each
other; where each serves as an effective prognostic biomarker in
lung cancer [6]. Therefore, better prognostic gene sets may be
identified through combined analysis of copy number and gene
expression data.
Chromosome alterations, including structural changes and
CNVs, have been extensively observed in tumorigenesis and are
speculated to drive tumor progression in multiple cancers [10].
Accordingly, exploration of CNVs might reveal the roles they
play in lung tumorigenesis. Using high resolution karyotyping
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regions have been detected: amplifications of 3p25–27 and 5p13–
14, and deletions of 3p21 and 9q21 [11]. Further investigations of
genes in these CNVRs do implicate several key players involved in
lung tumorigenesis. For instance, loss of docking protein 2 (DOK2)
as well as overexpression of baculoviral IAP repeat-containing 2/3
(BIRC2/3) can facilitate lung cancer cell proliferation and con-
tribute to lung tumor development [12,13]. Since genes located in
these common lung cancer CNVRs are candidate oncogenes or
tumor suppressors, an integrated analysis of their copy number
and expression levels may provide more information about
tumorigenesis in the lung.
Challenges arise, however, when integrating these multiple data
sources to identify consistent and reproducible molecular signa-
tures across different datasets. Using Venn diagrams to combine
significant genes derived from different data types usually produces
very few overlaps and leads to inaccurate results with high false-
positive rates. The traditional single-gene approach does help to
dissect complex diseases, but several limitations remain, especially
the difficulties in interpretation of biological meanings when
identified genes fall into non-overlapping functional categories and
pathways [14]. Even when investigating cancers with similar
histology, it is hard to obtain reproducibly significant gene
signatures. To overcome these challenges, several studies suggested
using functionally relevant gene sets instead of single-gene
approaches for statistical analysis to better elucidate biological
mechanisms [14,15,16].
In this study, we performed concurrent genome-wide
microarray analyses of CNVs and gene expression in non-
smoking female lung adenocarcinoma patients. By integration of
these two data types, we identified 475 genes located in CNVRs
that are differentially expressed between tumor and normal
tissues. Pathway analysis of these dysregulated genes revealed
seven significantly enriched canonical pathways, which impli-
cated two major biological functions in lung tumorigenesis.
Predictions of survival using these seven identified pathways
were validated in three independent cohorts, suggesting their
clinical relevance to serve as prognostic biomarkers for lung
cancer.
Results
Frequent copy number variable regions in lung
adenocarcinoma patients
Copy number variation analysis was performed using Affyme-
trix SNP 6.0 arrays, and each tumor tissue was compared
respectively to normal tissues from the same individual. As shown
in Fig. 1A, several recurrent CNVRs were detected, such as the
amplifications on chromosomes 1p, 5p, and 7p, and deletions on
3p, 8p, and 17p. To compare these identified CNVRs with the
aberration patterns reported previously, CNV analysis was
conducted on another lung adenocarcinoma cohort with both
copy number and gene expression microarray data from the same
individual [6]. Highly similar genomic altered patterns were
observed (Fig. 1A–B), and many genes located in the CNVRs were
reported as potential proto-oncogenes or tumor suppressors in
lung adenocarcinoma patients [17]. For instance, amplifications of
ARNT, TERT, and NKX2-1 and deletions on CDKN2A, CDKN2B
and PIPRD were also demonstrated in previous studies [6,17,18].
Among these frequent CNVRs, the most common amplification,
chromosome 7p, as well as the most common deletion,
chromosome 17p, occurred in approximately 60% of samples, a
percentage much higher than seen in other studies [6,17,18]. This
may imply that using adjacent normal tissue as a reference is able
to reduce individual differences and to uncover more general
CNVRs related to lung cancer.
Identification of CNV-driven differentially expressed
genes
To reduce individual heterogeneities and explore the genes in
the frequent CNVRs, we focused on the regions with at least 30%
(13/42) of samples showing copy number changes in the
following analyses. The corresponding gene expression probes
within these CNVRs were mapped to 5,086 unique genes
according to the annotation files provided by Affymetrix. To
evaluate whether the expression levels of the 5,086 genes were
associated with CNVs, patients were divided into two groups as
described in the methods: the ‘‘copy number varied’’ group and
the ‘‘copy number neutral’’ group. Next, for each one of such
genes, an unequal variance t-test was applied to the two groups,
by which we identified 609 differentially expressed genes
(p,10
25, Bonferroni correction: 0.05/5,086<10
25). Among
them, 475 genes (78%) showing concordance in the same
directional change of both CNV and gene expression were
selected for further exploration. Details on these 475 genes are
listed in Supplementary Table S1, and their corresponding
genomic locations are shown in Supplementary Fig. S1. To
validate the association between CNV status and gene expression
levels of these 475 genes in tumor tissue, the gene expression data
using one-way hierarchical clustering analysis was plotted in left
column of Fig. 2A, and the corresponding CNV status was
plotted in the right column. The heatmap revealed a highly
similar co-varying pattern between gene expression and CNV
(Fig. 2A). In addition to examining the dysregulated pattern
among the genes, the quantitative relationships between copy
number and expression level in tumor tissue were measured by
using Pearson correlation coefficients (Fig. 2B). The distribution
of correlation coefficients among the genes located in the CNVRs
in our data showed no clear difference to that among the whole
genome examined in the microarray. However, the correlation
coefficients among the CNV-driven genes were substantially
larger than that among other genes (Fig. 2C), suggesting that
these genes were regulated by their corresponding copy numbers
in lung tumor tissues. Two representative genes, EGFR and
TH1L, were illustrated to demonstrate the high correlations
between copy number and gene expression in tumor tissues
(Fig. 2D–E). These results indicate that CNVs are important
elements in driving downstream gene signaling in lung tumor-
igenesis.
Comparison of identified CNV-driven genes with Chitale
et al.
To further evaluate these selected 475 genes, the analysis
procedures in Fig. 3 were applied to the same dataset [6] used for
comparing the detected CNVRs in Fig. 1. The analysis results of
Chitale et al. identified 458 differentially expressed genes
(p,10
24), which were significantly overlapped with the 475 genes
Figure 1. Frequency plot of CNVs in lung adenocarcinoma patients. Red color represents amplification, and blue color represents deletion.
Y-axis shows the proportion of samples showing CNVs in the two datasets. (A) Our study, cohort of 42 adenocarcinoma patients. (B) The Chitale et al.
study [6], cohort of 193 adenocarcinoma patients.
doi:10.1371/journal.pone.0024829.g001
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Fisher’s exact test). Next, to examine the homogeneity of these
475 genes across these two datasets, 324 genes were correspond-
ingly mapped among the CNVRs detected in Chitale et al.
Distribution and box plots of the Pearson correlation coefficients
between copy number and expression level of the genes in tumor
tissues demonstrated obvious elevations when compared with the
total genes located in the CNVRs (Fig. S2A–B), which suggests
that our proposed method efficiently identifies reproducible
signatures in independent studies.
Dysregulated biological functions and pathways of CNV-
driven genes
To characterize the biological functions implicated by the 475
CNV-driven genes, Ingenuity Pathway Analysis was carried out to
describe gene-gene interaction networks and canonical pathways.
Fisher’s exact test identified 7 canonical pathways that were
significantly [2log (p).2.0] enriched among the 475 CNV-driven
genes (Table 1). The three pathways with the most significant p
values included IL-3 signaling, aminoacyl-tRNA biosynthesis, and
EIF2 signaling (Table 1). IL-3 is known to trigger anti-tumor
responses and retard tumor growth in NSCLC after injections
[19]. A previous study reported that a tRNA synthase, hDUS2,
participates in pulmonary carcinogenesis [20], though it is still not
clear why genes related to aminoacyl-tRNA biosynthesis were
dysregulated in lung cancer patients. EIF2 controlled mainly
protein synthesis through binding to initiator Met-tRNA
Met [21],
and its upstream regulators were involved in the signal
transduction cascade from IL-3. In addition to IL-3 signaling,
these genes were also downstream members shared by the other
four significantly enriched pathways, and thus a proposed
interaction network is displayed in Fig. 4. One major function
implicated by this network was cell survival regulation via AKT
signaling, which has been extensively studied and targeted in lung
cancer therapy [22,23]. In addition, there were multiple genes
involved in regulating cell proliferation and cell migration through
cytoskeleton reorganization, which further elucidated the biolog-
ical roles these differentially expressed genes with genomic
alterations may play in lung tumorigenesis.
Validation of identified pathways in three different
datasets
To validate the seven identified canonical pathways in
prediction of survival probabilities, we considered three indepen-
dent microarray datasets [24,25,26] for further investigation. (Our
own dataset was unsatisfactory for validation purposes because
most of the patients examined in our microarray experiments are
still alive.) Detailed information about the survival evaluation
procedures is described in Methods. For each dataset, the
empirical p for testing each pathway against the null baseline is
listed in Table 2. The results indicated that all genes in their
respective pathways are significant survival predictors for all three
datasets, except those involved in aminoacyl-tRNA biosynthesis.
The two pathways with the most significant and consistent p values
were IL-3 signaling and ephrin receptor signaling, and their
corresponding survival prediction accuracy was assessed with
Figure 2. Expression profiles of CNV-driven genes. (A) Hierarchical clustering of the 475 CNV-driven genes. For gene expression (left column),
the input data of each gene was normalized to its Z-value, which was obtained through two-step calculations. First, for each gene, corresponding
copy number neutral samples were used as a normalization baseline, that is, the median probe intensity in the normal tissue was subtracted from
probe intensities in all the samples. Next, adjusted probe intensity was divided by the standard deviation of probe intensity among copy number
neutral samples to get the normalized Z-value. One-way hierarchical clustering was performed on these Z-values of gene expression. Red color
indicates up-regulated genes; green color indicates down-regulated genes. For CNV status (right column), the corresponding chromosome changes
are plotted in the same gene order as gene expression. Red color denotes amplification and green denotes deletion. (B) Distribution of Pearson
correlation coefficients among the 475 CNV-driven genes was plotted against that from the genes located within the CNVRs. (C) Box plot of
correlations among the 475 CNV-driven genes. (D–E) The Pearson correlation coefficient was utilized to describe the association between copy
number and gene expression in tumor tissues for (D) EGFR and (E) TH1L. Copy number is shown on the left y-axis; gene expression is shown on the
right y-axis in a log scale.
doi:10.1371/journal.pone.0024829.g002
Figure 3. Flowchart for identifying CNV-driven genes based on
CNV and expression data from paired tissues. Numbers in
parentheses correspond to samples of Taiwan female lung cancer.
doi:10.1371/journal.pone.0024829.g003
Table 1. Enriched canonical pathways identified by Ingenuity
Pathway Analysis among the genes with both copy number
variation and differential expression.
Canonical Pathway 2log(p-value)
a
Associated
Gene Number
b
IL-3 Signaling 2.83 7
Aminoacyl-tRNA Biosynthesis 2.55 5
EIF2 Signaling 2.37 7
PTEN Signaling 2.21 7
Renal Cell Carcinoma Signaling 2.20 6
Oncostatin M Signaling 2.03 4
Ephrin Receptor Signaling 2.02 10
aThe significance level of each canonical pathway was determined by Fisher’s
exact test in Ingenuity Pathway Analysis.
bThe associated gene number represents the number of dysregulated genes
involved in the corresponding canonical pathway.
doi:10.1371/journal.pone.0024829.t001
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mances based on different numbers of genes in these two pathways
were also evaluated by examining all possible combinations of the
7 or 10 genes in Kaplan-Meier survival analysis. As shown in
Supplementary Fig. S3, the prediction performances improved
gradually when more genes were included for survival analysis,
and the lowest p-values were reached by using the 7 genes together
(or 10 genes in the second pathway). It is worth noting that even
though these CNV-driven genes were identified based on the pure
lung adenocarcinoma samples, these genes demonstrated effective
prediction of survival in three lung cancer datasets including
patients with squamous cell carcinoma subtypes. We conclude that
these differentially expressed genes with genomic alterations may
not only participate in lung tumorigenesis but may also represent a
prognostic signature for clinical use.
Discussion
It is well-known that there are many causative elements
contributing to cancer progression and tumorigenesis, such as
transcriptional alterations, sequence mutations, and genomic
changes. Among these complicated factors, CNVs have been
widely reported to serve as a key driver of transcriptome
dysregulation [4]. Therefore, to account for the complex relation-
ship between copy number and gene expression, we performed an
integrated analysis in paired lung adenocarcinoma tissue specimens
to identify differentially expressed genes with concordant genomic
alterations. Survival analyses demonstrated that the identified gene
sets were consistently associated with clinical outcomes in three
independent lung cancer cohorts—such consistent findings are not
easily obtained by examining mRNA expression profiles alone [3].
Figure 4. Proposed interaction network of dysregulated pathways enriched by the CNV-driven genes. Cellular response is represented
by solid boxes. Genes showing amplification and up-regulation are colored in red; genes showing deletion and down-regulation are colored in green.
The lines between proteins indicate evidence inferred from the literature. The superscript numbers correspond to the ranking of enrichment p-values.
doi:10.1371/journal.pone.0024829.g004
Integrations of CNV and GE in Lung Adenocarcinoma
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24829CNV analysis provided general insights into genomic alterations
in lung adenocarcinoma (Fig. 1), and the identified CNVRs were
highly similar to those reported previously [6,17,18]. However, a
notable difference was that the identified CNV frequency among
our patient samples (30,60%) was much higher, which may be
attributed to the use of adjacent normal tissue, not the common
reference genome, as the reference baseline. Because copy number
polymorphisms exist commonly in the human genome [27,28],
comparison with the common reference genome may increase the
possibility of enrolling more genomic alteration hotspots with
lower degree of participation in lung tumorigenesis. Moreover,
tumor tissues are usually inhomogeneous across patients, and thus
incorporating adjacent normal tissue from the same individual into
the analysis may help to reduce variations caused by individual
heterogeneity.
To identify differentially expressed genes involved in lung
tumorigenesis, we applied statistical analyses on gene expression
data between tumor and normal tissues rather than between
tumor tissues with and without copy number variations. Similar
patterns of fold changes were illustrated in both analyses
(Fig. S4), but minor differences were observed while examining
tumor tissues only. It is possible that gene expression profiles
had already been dysregulated to adapt to proper function
in tumor tissues during carcinogenesis. Therefore, even though
adjacent normal tissues may be partly contaminated by
tumor samples, they still provide a better comparison baseline,
which resembled regular gene expression profiles in healthy
lung.
Compared to other cytogenetic reports about lung cancer, we
observed different genomic states on chromosome 5q. Several
studies reported the association between deletion of this chromo-
somal region and small cell and squamous cell lung cancer
subtypes [29,30,31], and it was also pointed out that this deletion
may be associated with smoking history [32]. Nevertheless,
amplifications of 5q have been detected in other adenocarcinoma
studies [33,34]. This controversy may come from differences in
lung cancer subtypes and/or in history of smoking. Here, in our
study, only women with non-smoking lung adenocarcinoma were
recruited and thus no comparison group is available. For further
investigation to elucidate the role this region may play, data from
smoking females may be of help.
Regarding the 5,086 genes residing in the CNVRs, signifi-
cantly different expression associated with CNVs was detected in
609 genes (12%), a proportion comparable to that of previous
studies [4,35]. Among the 609 selected genes, 475 genes (78%)
showed positive correlation between CNV and mRNA expres-
sion and 134 genes (22%) showed negative correlation. The most
positively correlated gene, C20orf11, was identified here but no
functional study is available at this time. However, the second
gene, TH1L, has been shown to play an important role in many
processes of inflammation and pulmonary fibrosis in lung [36],
and there were two other reports indicating that TH1L may be
associated with tumor development [37,38]. The knockdown of
TH1L was able to trigger several molecular and cellular changes
correlated with epithelial-mesenchymal–transitition in MCF7
cells [37], and TH1L participates in the regulation of MAPK
signaling [38], which was closely associated with lung cancer. In
addition, the elevated correlations of the 475 concordantly
changed genes further evidenced that our statistical approaches
are able to efficiently identify dysregulated genes based on
CNVs.
On the other hand, the reason why the other 134 genes
displayed discordant changes remains unclear. The occurrence of
negative correlation could result from just random chance, or,
alternatively, from the existence of other regulatory mechanisms
that inhibit genomic alterations, such as miRNA regulations, gene
mutations, and epigenetic methylations [39]. Tumor tissues may
suffer damage if essential genes for tumor development undergo
CNVs that amplify tumor suppressors or delete oncogenes. For
instance, both the most negatively correlated gene, RTN1,
involved in detoxification in lung cancer [40], and a potential
lung cancer tumor suppressor, SEMA5A [41], were significantly
down-regulated though frequently amplified in tumor tissues.
Therefore, the relevance of these discordant genes to lung cancer
deserves further investigation.
To further explore whether these 475 CNV-driven genes were
sample dependent, the same statistical approaches shown in Fig. 3
were performed only in non-smoking lung cancer women from the
Chitale et al. study [6]. After excluding those without both CNV
and gene expression data, only 28 samples were remained for
further analysis. The results showed higher similarity in the gene
list (80% vs. 68%), and lower significant levels of overlapping with
our data (p=0.000005 versus p=0.0034, Fisher’s exact test).
Moreover, the CNV frequency of amplifications at 5q was much
higher (,25%) in these non-smoking female patients (Fig. S5),
which agreed with previous report that smoking history was
associated with the deletion of 5q [32]. Since similar results were
observed in female non-smokers and mixed population, these
results indicated that our algorithm in integrating copy number
variation with gene expression could be applied to other types of
lung cancer.
The major cellular function implicated by the interaction
network summarized from the 7 canonical pathways was cell
survival regulation (Fig. 4). It is well-known that EGFR participates
in the development and progression of lung cancer [42], and its
amplifications and mutations correlate with effective response to
several EGFR tyrosine kinase inhibitors (TKIs) for NSCLC
therapy [43]. Better treatment outcomes of EGFR-TKIs were
shown in females, non-smokers, and patients with lung adenocar-
cinoma, and thus it is not surprising to observe frequent
amplifications (52%) and mutations (83%) of EGFR in our results.
IKBKE was indicated as a potential oncogene by phosphorylating
inhibitors of NFKB to prolong cell survival, and its amplifications
and over-expressions were seen in over 30% of breast cancer
patients and cell lines [44]. Though the deletions of ERK2 seemed
to be contradictory, recurrent loss of 22q (29%) was also detected
in another study with a similar population [33]. Minor expression
ratio changes between tumor and normal tissues were observed in
this study (0.7,1.1) and the other three lung cancer cohorts
(0.9,1.1) examining paired samples [45,46,47]. Moreover,
activation of ERK2 signaling requires phosphorylation [48], which
Table 2. Empirical p-values of the canonical pathways
a.
Canonical Pathway GSE3141 GSE10245 GSE8894
IL-3 Signaling 0.0027 0.0311 0.0002
Aminoacyl-tRNA Biosynthesis 0.1133 0.5117 0.1503
EIF2 Signaling 0.0182 0.0491 0.0230
PTEN Signaling 0.0098 0.0234 0.0048
Renal Cell Carcinoma Signaling 0.0018 0.0372 0.0080
Oncostatin M Signaling 0.0129 0.0042 0.0721
Ephrin Receptor Signaling 0.0055 0.0001 0.0171
aThe significance levels were determined by comparison with null baselines
created by random selections.
doi:10.1371/journal.pone.0024829.t002
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thus ongoing research efforts are warranted to further elucidate
such mechanisms. In addition to cell survival, cell migration
through regulation of integrin was another function implicated by
this interaction network. Integrin-dependent interaction with the
surrounding extracellular matrix correlates with invasive abilities
in lung cancer and other cancer types [49]. Lastly, the proposed
interaction network was similar to one identified by integrating
Figure 5. Kaplan-Meier survival curves of genes associated with IL-3 signaling or ephrin receptor signaling pathways. For each
pathway in a Cox regression model, the influence of each variable was quantified by the estimated beta coefficient value. These beta values were
multiplied by their original variables respectively to summarize the Cox regression score for each patient examined. Next, patients were divided into
two groups according to the Cox regression scores: (1) the ‘‘High Score’’ group, in which scores were higher than the median scores in all samples,
and (2) the ‘‘Low Score’’ group, in which scores were lower than the median scores in all samples. Kaplan-Meier survival analyses were performed on
patients in the ‘‘High Score’’ and ‘‘Low Score’’ groups, and the empirical p values were determined after being compared with null baselines. (A–C)
Seven genes involved in the IL-3 signaling pathway. (A) GSE3141 [24]. (B) GSE10245 [26]. (C) GSE8894 [25]. (D–F) Ten genes involved in the ephrin
receptor signaling pathway. (D) GSE3141. (E) GSE10245. (F) GSE8894. Detailed gene lists were shown in Supplementary Table S4.
doi:10.1371/journal.pone.0024829.g005
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cancers [50], which suggests that these dysregulated genes are
highly associated not only with lung tumorigenesis, but also with
multiple cancers.
The survival predictions using these CNV-driven genes were
effective in lung adenocarcinoma and, surprisingly, in squamous
cell carcinoma patients as well (Table 2). To further explore
whether these CNV-driven genes are independent of lung cancer
subtype, the survival prediction was examined in NSCLC patients
with only squamous cell carcinoma [51]. Although less satisfactory
results were observed (Table S2), several genes involved in the
ephrin receptor signaling pathway still showed effective prediction
ability, concurring that genes participation in regulation of integrin
may become dysregulated during the tumorigenic process across
different cancer types [49]. Therefore, these dysregulated genes
with CNVs may become promising targets for further pharmaco-
logical research in cancer therapy.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all subjects and/or
guardians for the use of their tissue samples. This study was
approved by National Taiwan University Hospital Research
Ethics Committee and The Institutional Review Board of
Taichung Veterans General Hospital.
Sample preparation and microarray experiments
One hundred and twenty paired lung tumor and adjacent
normal tissues were collected from patients admitted to National
Taiwan University Hospital or Taichung Veterans General
Hospital. Fourty-two pairs of lung tumor and normal specimens
from non-smoking adenocarcinoma female patients were analyzed
by using Affymetrix SNP 6.0 and Affymetrix U133plus2.0
microarrays, after extraction of DNA and RNA according to the
manufacturers’ instructions. The mean 6 SD age of these samples
was 62610 years, and 71% (30/42) of the patients were in stage I
or II. Summary patient characterisitics are shown in Table S3.
The microarray data have been submitted to the Gene Expression
Omnibus database (accession number GSE19804).
Identification of CNV-driven differentially expressed
genes
To investigate genomic alternations, we used an Affymetrix
Genome-Wide Human SNP 6.0 array containing 1.8 million SNP
and CNV probes in total. The microarray data were imported into
the Partek Genomic Suite to perform CNV analysis. Since both
tumor and normal tissues from the same individual were
examined, each tumor tissue could be compared with its
counterpart, the normal tissue, respectively. A genomic segment
was defined if the following criteria were all satisfied: minimum
consecutive genomic markers $100, p-value#0.001, and signal-to-
noise ratio (SNR)$0.3. These identified segments were indicated
as copy number variated if their copy number changes were at
least 0.3; that is the copy number of an amplified region was
higher than 2.3, and the copy number of a deleted region was
Table 3. Sample characteristics of the three microarray
datasets used for survival evaluation.
Characteristics GSE3141 GSE10245 GSE8894
a,b
Sample number 111 58 136
Microarray platform Affymetrix
U133plus2.0
Affymetrix
U133plus2.0
Affymetrix
U133plus2.0
Age NA 64.569.3 60.869.6
Tumor types
Adenocarcinoma 58 (52%) 40 (69%) 60 (44%)
Squamous 53 (48%) 18 (31%) 76 (56%)
Gender NA
Male 44 (76%) 103 (24%)
Female 14 (24%) 33 (76%)
aTwo samples were removed due to lack of age information.
bRecurrence-free survival was used here.
doi:10.1371/journal.pone.0024829.t003
Figure 6. Flowchart for clinical validation of CNV-driven genes. Three independent lung cancer datasets retrieved from Gene Expression
Omnibus [53] were examined: GSE3141 [24], GSE8894 [25], and GSE10245 [26].
doi:10.1371/journal.pone.0024829.g006
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lung adenocarcinomas, only regions showing changes in at least
30% (13/42) of the samples were analyzed further (step 1 in Fig. 3).
The overlapping genes within these identified CNVRs were
obtained after searching through the Affymetrix annotation file
version 30 (step 2: 5,086 genes). To evaluate whether expression of
these genes was related to CNV, patients were classified into two
groups according to their CNV status: one group is for copy
number variated (gain/loss), and the other group for copy number
neutral. For each one of the 5,086 genes, an unequal variance t-
test was applied to the gene expression variation between copy
number variated tumor tissues and copy number neutral normal
tissues (step 3: 609 genes). To identify CNV-driven genes, only
genes with concordant changes in copy number and gene
expression were collected for further analyses (step 4: 475 genes).
Visualization of the identified genes, including CNV statuses and
expression levels in tumor tissues, was illustrated by hierarchical
clustering in the Genesis program [52] in Fig. 2.
Comparison of identified CNV-driven genes with Chitale
et al.
To further demonstrate the usefulness of the procedures in the
flowchart for identifying CNV-driven genes (Fig. 3), another lung
cancer dataset withcopynumberandgene expression data from the
same individual was investigated [6]. The same analysis procedures
were applied, except that the comparision of differentially expressed
genes in step 3 was conductedon only tumor tissues. In otherwords,
gene expression variables were examined on tumor tissues between
copy number variated and neutral samples since no adjacent
normal tissues were studied in this cohort.
Validation of CNV-driven genes and pathways with three
different datasets
To characterize which biological functions and canonical
pathways the significantly differentially expressed genes are part
of, Ingenuity Pathway Analysis wascarried out.Afteridentifying the
pathways enriched by the CNV-driven genes, their performance in
prediction of survival probabilities was evaluated. Here, we
considered three microarray datasets (summary statistics are given
in Table 3) with published survival outcomes [24,25,26], which
were retrieved from Gene Expression Omnibus [53], to conduct the
following validation procedures (Fig. 6). Since intensity distributions
were usually inconsistent in different studies, the probe intensities
were first standardized across all the patients respectively by the Z-
score method. For the genes involved in a specifc canonical
pathway, the Cox regression model was used to evaluate the
association between expression of these CNV-driven genes and
survival outcomes with the available clinical data. In a Cox
regression model, the influence of each variable was quantified by
the estimated beta coefficient value. These beta values were
multiplied by their original variables respectively to summarize
the Cox regression score for each patient examined. Next, patients
were divided into two groups according to the Cox regression
scores:(1)the‘‘HighScore’’group,inwhichscoreswerehigherthan
the median scores in all samples, and (2) the ‘‘Low Score’’ group, in
which scores were lower than the median scores in all samples.
Kaplan-Meier survival analyses were performed on patients in the
‘‘High Score’’ and ‘‘Low Score’’ groups to evaluate the association
between CNV-driven genes and survival outcomes.
Furthermore, to establish a null baseline for comparison, Cox
regression and Kaplan-Meier survival analyses were conducted
again but with genes randomly selected from the original pool,
where the number of genes was kept the same as the pathway under
study. To incorporate the heterogeneity of the genes selected,
100,000 iterations were performed for each pathway. Empirical p
values of the identified pathways were then determined by
comparing the Kaplan-Meier survival prediction probability with
the null baselines; that is, the ranking of the Kaplan-Meier p-values.
Supporting Information
Figure S1 Genomic locations of the CNV-driven genes.
Y-axis shows the proportion of samples showing CNVs.
(TIF)
Figure S2 Pearson correlation coefficients of the 324
overlapped CNV-driven genes in the Chitale et al. study.
(A) Distribution of correlations among the CNV-driven genes was
plotted against that from the genes located within the CNVRs. (B)
Box plot of correlations among the 324 CNV-driven genes.
(TIF)
Figure S3 Prediction performances based on different
numbers of genes in the IL-3 signaling and ephrin
receptor signaling pathways. Kaplan-Meier survival curves
were used to evaluate the prediction performances using all
possible combinations of the 7 or 10 genes within the two
pathways. X axis denotes the number of genes used in survival
analysis, and Y axis represents the corresponding average Kaplan-
Meier 2log p-values.
(TIF)
Figure S4 Fold changes of expression relative to normal
or tumor tissues. Relative expression level is shown on the x-
axis in a log scale; frequency of genes is shown in the y-axis.
(TIF)
Figure S5 Frequency plot of CNVs in the non-smoking
lung adenocarcinoma women from the Chitale et al.
study. Red color represents amplification, and blue color
represents deletion. Y-axis shows the proportion of samples
showing CNVs in the dataset.
(TIF)
Table S1 Statistics of the 475 CNV-driven genes.
(PDF)
Table S2 Empirical p-values of the canonical pathways
in GSE4573
a
(PDF)
Table S3 Sample characteristics of lung cancer patients
examined by both Affymetrix SNP6.0 and Affymetrix
U133plus 2.0 arrays.
(PDF)
Table S4 Genes involved in the IL-3 signaling and
ephrin receptor signaling pathways.
(PDF)
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